Leflunomide:: new antirheumatic drug -: Effect on pregnancy outcomes

被引:0
|
作者
Kozer, E
Moretti, ME
Koren, G
机构
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
QUESTION I am treating a 34-year-old woman with rheumatoid arthritis. She began taking the new drug leflunomide (Arava (R)) 6 months ago and had good clinical response. She is now planning her first pregnancy. What should she do? ANSWER Leflunomide is a new and effective disease-modifying antirheumatic drug. Animal studies have shown an increased rate of malformations and fetal death in various species, but their are no data on pregnancy outcomes in humans treated with leflunomide. Since the drug has a prolonged and unpredictable elimination half-life, it should be stopped during pregnancy. The manufacturer recommends that patients who wish to become pregnant be treated with cholestyramine, which enhances elimination.
引用
收藏
页码:721 / 722
页数:2
相关论文
共 50 条
  • [1] Optimization of antirheumatic leflunomide therapy by therapeutic drug monitoring
    van Roon, EN
    Botta-Steeneken, NA
    Jansen, TLTA
    Wilffert, B
    Brouwers, JRBJ
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 : R156 - R156
  • [2] THERAPEUTIC EFFECTS OF LEFLUNOMIDE, A NEW ANTIRHEUMATIC DRUG, ON GLOMERULONEPHRITIS INDUCED BY THE ANTIBASEMENT MEMBRANE ANTIBODY IN RATS
    OGAWA, T
    INAZU, M
    GOTOH, K
    INOUE, T
    HAYASHI, S
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1991, 61 (01): : 103 - 118
  • [3] Anticancer effect of the antirheumatic drug leflunomide on oral squamous cell carcinoma by the inhibition of tumor angiogenesis
    Niwata, Chieko
    Nakagawa, Takayuki
    Naruse, Takako
    Sakuma, Miyuki
    Yamakado, Nao
    Akagi, Misaki
    Ono, Shigehiro
    Tobiume, Kei
    Gao, Jing
    Jimi, Eijiro
    Ohta, Kouji
    Aikawa, Tomonao
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [4] Antirheumatic drug therapy during pregnancy
    Soscia, PN
    Zurier, RB
    BULLETIN ON THE RHEUMATIC DISEASES, 1997, 46 (02) : 2 - 4
  • [5] Pregnancy outcomes in patients treated with leflunomide, an in vivo precursor of the multiple sclerosis drug teriflunomide
    Truffinet, P.
    Afsar, S.
    Davenport, L.
    Purvis, A.
    Poole, E. M.
    Henson, L. J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 621 - 621
  • [6] Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide
    Henson, Lily J.
    Afsar, Salman
    Davenport, Lynn
    Purvis, Annie
    Poole, Elizabeth M.
    Truffinet, Philippe
    REPRODUCTIVE TOXICOLOGY, 2020, 95 : 45 - 50
  • [7] OPTIMIZATION OF ANTIRHEUMATIC DRUG-TREATMENT IN PREGNANCY
    OSTENSEN, M
    CLINICAL PHARMACOKINETICS, 1994, 27 (06) : 486 - 503
  • [8] SULPHASALAZINE - A NEW ANTIRHEUMATIC DRUG
    PULLAR, T
    CAPELL, HA
    BRITISH JOURNAL OF RHEUMATOLOGY, 1984, 23 (01): : 26 - 34
  • [9] Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes
    Berard, Anick
    Zhao, Jin-Ping
    Shui, Irene
    Colilla, Susan
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 500 - 509
  • [10] A NEW ANTIRHEUMATIC DRUG - MIDALGYL
    VIGNON, G
    LAURENT, J
    KOPP, N
    PRESSE MEDICALE, 1970, 78 (48): : 2145 - &